▴ Everolimus is an immunosuppressant that blocks growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells.
▴ Oral everolimus 0.75 or 1.5mg twice daily significantly reduced the incidence of the primary composite endpoint, efficacy failure 6 months after transplantation, compared with azathioprine 1–3 mg/kg/day, in adult cardiac transplant recipients. All patients also received baseline immunosuppression with ciclosporin and corticosteroids.
▴ The incidence of efficacy failure remained significantly lower in everolimus recipients than in those receiving azathioprine 1 and 2 years after cardiac transplantation. However, graft and patient survival rates at 1 year were similar in patients receiving everolimus or azathioprine.
▴ The incidence of graft vasculopathy 2 years after transplantation was significantly lower in cardiac transplant recipients receiving everolimus 0.75mg twice daily than in those receiving azathioprine.
▴ The combined incidence of biopsy-confirmed acute rejection, graft loss, death, or loss to follow-up was similar in adult patients receiving everolimus 1.5 or 3 mg/day or mycophenolate mofetil (MMF) 2 g/day 1 or 3 years after renal transplantation. Patients also received baseline immunosupression with ciclosporin and corticosteroids.
▴ Compared with azathioprine and MMF, everolimus is associated with a lower incidence of cytome-galovirus infection in cardiac and renal transplant recipients. Everolimus has been associated with thrombocytopenia, leucopenia and elevated serum lipids and creatinine.
- 11.Delaney MP, Higgins RM, Morris AG. FK506 and the rapamycin analogue, SDZ RAD do not have antagonistic effects on lymphocytes from renal transplant patients [abstract no. 657]. Am J Transplant 2001; 1 Suppl. 1: 301Google Scholar
- 21.Pirron U, Kovarik JM, Eisen H, et al. Longitudinal pharmacokinetics of everolimus in de novo heart transplant patients and its influence on cyclosporine [abstract no. 0626]. Transplantation 2002 Aug 27; 74 Suppl.: 211Google Scholar
- 22.Kovarik JM, Sabia H, Rouilly M, et al. Influence of renal and hepatic impairment on everolimus pharmacokinetics: are dose adjustments necessary? [abstract no. 989]. Am J Transplant 2001; 1 Suppl. 1: 385Google Scholar
- 34.Curtis J, Nashan B, Kovarik JM, et al. RAD (everolimus) pharmacokinetics are unaltered with full-dose versus reduced-dose cyclosporine [abstract no. 651]. Am J Transplant 2001; 1 Suppl. 1: 299Google Scholar
- 38.Hauck W, Delgado D, Perrone S, et al. Everolimus reduces cardiac allograft vasculopathy in de novo heart transplant recipients: 24 month follow-up [abstract no. 153]. Can J Cardiol 2003 Oct; 19 Suppl. A: 90AGoogle Scholar
- 39.Kaplan B, Tedesco-Silva H, Mendez R, et al. North/South American, double-blind, parallel group study of the safety and efficacy of Certican. Am J Transplant 2001; 1 Suppl. 1: 475Google Scholar
- 40.Vitko S, Margreiter R, Weimar W, et al. International, double-blind, parallel group study of the safety and efficacy of Certican™ (RAD) versus mycophenolate mofetil in combination with Neoral® and steroids [abstract no. 1337]. Am J Transplant 2001; 1 Suppl. 1: 474Google Scholar
- 41.Oppenheimer F, Oyen O, Viljoen H, et al. 36-Month results of an international study with everolimus for the prevention of allograft rejection in de novo kidney transplant recipients [abstract no. 1201 plus oral presentation]. Am J Transplant 2003; 3 Suppl. 5: 459–1201Google Scholar
- 42.Curtis J, Nashan B, Ponticelli C, et al. One year results of multicenter, open-label trial on safety and efficacy of Certican™ (RAD) used in combination with Simulect®, corticosteroids, and full or reduced dose Neoral® in renal transplantation [abstract no. 1335]. Am J Transplant 2001; 1 Suppl. 1: 474Google Scholar
- 43.Dantal J, Vitko S, Margreiter R, et al. Reduced incidence of CMV infection in kidney transplant recipients treated with everolimus (Certican, RAD) [abstract no. 0354]. Transplantation 2002 Aug 27; 74 Suppl.: 125Google Scholar
- 47.Holmes MW, Chilcott JB, Walters SJ, et al. Economic evaluation of everolimus (Certican™1) versus mycophenolate mofetil as part of triple immunosuppressive therapy in de novo renal transplant recipients [abstract no. 2148; plus poster]. Transplantation 2002 Aug 27; 74 Suppl.: 435CrossRefGoogle Scholar
- 48.Novartis. Summary of the product characteristics: everolimus. Novartis, 2003 DecGoogle Scholar
- 49.Novartis Pharmaceutical Corporation. New Novartis drug Certican® approved in first European market [media release; online]. Available from URL: http://www.novartis.nl/pdf/nieuws/juli2003/pr230703certicanapprovalsweden.pdf [Accessed 2003 Nov 21]